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Abstract: Numerous studies have been published suggesting that emergency contraception (EC) is
used repeatedly, but a lack of information regarding the profile of users makes it difficult to evaluate
actual consumer habits. The aim of this study was to obtain information regarding the profile of
users who obtain EC and other factors that might play a role, and to provide criteria to evaluate and
improve the strategies of current contraceptive programs. This was an observational one-year study
based on surveillance data on the provision of EC to women of reproductive age in 60 community
pharmacies in Catalonia, Spain. In total, 941 notifications of dispensation of EC in Catalonia were
received. A total of 44.2% of users said it was not the first time that they had taken the medication
(repeat user). The percentage of users who used condoms was lower in repeat users compared to
first-time users (56.7% vs. 64.4%, p < 0.05). A total of 25.7% of users stated that they did not use
any barrier contraceptive method. The use of natural methods in repeat users was 53.8% in the
subgroup who requested the medication after 48 h, significantly higher than in users who obtained
the medication within the first 24 h (p < 0.05). A high percentage of repeat users with risky sexual
behaviors were detected, suggesting that new measures must be implemented to provide information
for this method, together with educational and preventive strategies.
Keywords: emergency contraception; contraceptive method; levonorgestrel; ulipristal acetate; com-
munity pharmacies; health services administration
1. Introduction
The primary aim of emergency contraception (EC) is to prevent an unwanted preg-
nancy following unprotected sexual intercourse. Its use has no medical contraindications
and it is indicated mainly in women of reproductive age who had unprotected sex, either
because they did not use contraception or the contraception failed due to inadequate or
incorrect use, or because of sexual assault in which the woman was not protected by an
effective contraceptive method [1–4].
The criteria for prescribing this medication are that it must not be used routinely and
must never be considered a regular method of contraception, since users are not protected
against sexually-transmitted diseases (STDs), including the human immunodeficiency
virus (HIV) [1–4].
The medicinal products currently used in Spain as EC are post-coital pills, which
contain levonorgestrel (LNG) and ulipristal acetate (UPA) as the active substances. They
obtained marketing authorization in 2001 and 2009, respectively, and were initially subject
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to medical prescription. It was not until the end of 2009, in the case of LNG, and 2015, in
the case of UPA, that they were dispensed over the counter. This allowed the population to
have increased access to the medication and accorded the community pharmacist a more
active role and greater responsibility in the indication and dispensing of EC [4].
For this reason, numerous practical guidelines on EC have been published in Spain
since 2009, in order to ensure the rational use of the medication, guide and standardize
the actions of community pharmacists to meet the demand for provision, and improve
educational and preventive aspects so that users adopt safe sexual behavior [4–6].
In Europe, the World Health Organization (WHO) recommends the administration of
EC as a single-dose pill that contains 1.5 mg of LNG or 30 mg of UPA. Both drugs affect the
ovulation process, delaying follicular rupture, with no effects with respect to implantation
of the ovum. This indicates that the efficacy of the medication decreases as time passes after
unprotected intercourse. It has also been shown that, if administered after implantation of
the ovum, EC is not effective at the doses indicated [1–4].
With regard to the safety of this medication, the side effects described in the product
information sheets are mainly mild and transient. The most common adverse reactions are
the onset of nausea and changes in the time and type of bleeding in the following menstrual
period. Common adverse reactions have been reported, such as headache, myalgia, and
fatigue, which typically disappear 48 h after administration of the medication. Uncommon
adverse reactions identified include anorexia, ectopic pregnancy, exanthema, miscarriage,
and weight gain. Multiple serious adverse events, including convulsion, ectopic pregnancy,
febrile neutropenia, stroke, abdominal hernia, anaphylaxis, cancer, ovarian cyst rupture,
serious infections, and suicidal ideation, have been reported [7,8].
Numerous studies have been published suggesting that this contraceptive method is
used repeatedly, but a lack of information regarding the profile of users and their perception
of EC as an urgent requirement makes it difficult to evaluate actual consumer habits [9].
For this reason, data that validate these suspicions need to be collected.
Currently, there are new forms of epidemiological surveillance in our setting that seek
to improve the effectiveness and efficacy of detection systems and to incorporate other
health indicators, such as population behavior and habits. Information on processes linked
to these indicators is usually sparse or incomplete, and is typically difficult to identify with
traditional surveillance tools. These processes require the integration of several agents
with different professional profiles as well as having detection tools closer to the site of
demand or where the event occurs. In this sense, the community pharmacist has enormous
potential as a first-line agent to report the rational use of medicinal products and to educate
the population to adopt safe sexual behavior [10].
In Catalonia, a region of Spain situated in South Europe, a pilot project on sentinel
pharmacies, carried out in 2016, studied the dispensation of EC. The information recorded
obtained the initial data on the profile of users and their patterns of behavior [11]. Never-
theless, a larger study is needed to obtain data that will allow us to develop new health
indicators generated by the care dynamics of the pharmacy, reinforce traditional surveil-
lance systems, and provide an overview of the use of this method.
Thus, the aim of this study was to obtain information regarding the profile of users
who obtain EC and other factors that may be involved, and to provide criteria to evaluate
and improve the strategies of current contraceptive programs.
2. Materials and Methods
This was a descriptive, observational, prospective, one-year study (July 2018–June
2019) based on surveillance data on the provision of EC in women of reproductive age (age
range of 16–55 years) in community pharmacies in Catalonia, Spain, that were a part of the
sentinel pharmacy network.
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2.1. Sampling Frame
The Catalan sentinel pharmacy network, composed of 60 community pharmacies
scattered throughout the region, was constituted proportionally to a stratification of the
population of Catalonia based on criteria of representativeness, ensuring a coverage of 2.5%
of the Catalan population. For the representativeness analysis, we considered the basic
health areas (BHAs) of each healthcare sector of the region, establishing the proportion
of urban, semi-urban, and mountain pharmacies; and considering geographical, socio-
economic, demographic, epidemiological, cultural, and homogeneous communication
channels.
2.2. Data Collection
Data were obtained using an 18-item electronic form that the users answered at the
point of EC provision in the sentinel pharmacies. All cases were registered by 122 pharma-
cists from the 60 community pharmacies. The following variables were recorded:
• Code and name of sentinel pharmacy;
• Date of EC dispensation;
• National code and name of medicinal product;
• User sex (male, female);
• Age of the user;
• Who the medication is for (choice between personal use, partner, friend, daughter,
and other family member);
• Postal code of the population of residence: to determine if the person searches for the
medication in a nearby pharmacy;
• Time from unprotected sex (hours);
• Time since the last menstrual period (weeks);
• Contraceptive method normally used;
• First EC dispensation or not;
• If it is not the first dispensation, indicate the time elapsed since the last dispensation
(less than 6 months, between 6 months and 1 year, more than 1 year);
• If it is not the first dispensation, indicate which medication was previously taken;
• If it is not the first dispensation, indicate if the patient has previously had any adverse
reactions;
• Suspected adverse reactions reported to the pharmacovigilance center (yes or no);
• Description of pharmaceutical action performed;
• Availability of an EC kit consisting of a condom and additional informative material
(yes or no);
• Observations (free text field to indicate any relevant aspect during the EC dispensa-
tion);
The data collection tool was validated through a pilot test carried out in 2016 in 21
community pharmacies in Barcelona, Catalonia, Spain [11].
All confidential information collected was recorded in the Applications Portal of the
Ministry of Health, accessible by username and password through the Drugs and Pharmacy
Channel website.
The participation rate was 99.6% (941 of 945 users). Users were informed and signed
the informed consent to participate in the study.
2.3. Data Analysis
Subject characteristics that were categorical variables were summarized as counts
and percentages. Continuous variables were summarized as means with standard de-
viations. The results related according to the type of pharmacy selected were grouped
into 3 categories: urban, semi-urban, and mountain. For the statistical analysis, the χ2
test was used for the study of the categorical variables and the Student t-test to compare
continuous variables. A p-value < 0.05 was considered statistically significant. All analyses
were conducted with SPSSS software, version 18 (SPSS Inc., Chicago, IL, USA).
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3. Results
3.1. Incidence Data
During the study, 941 notifications of dispensation of EC in Catalonia were received
(Figure 1). The months that correspond to holiday periods experienced a higher incidence
in the number of dispensations; the highest were in the month of March 2019, which
coincides with Easter, with an incidence of 244 per 100,000 women of reproductive age,
and the summer months of August and September 2018, with an incidence of 233 per
100,000 women of reproductive age (Figure 1).
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Figure 1. Number of EC dispensations and cumulative incidence per month. Catalonia, 2018–2019. Significant differences:
* vs. the incidence in December (p < 0.05).
Similarly, urban areas repo ted a higher incidence in the numb r of dispensations with
respect to semi-urban and mountain areas (p < 0.001 and p < 0.05, respectively) (Figure 2).
With respect to the type of medication, LNG was dispensed in 78.9% of cases and
UPA in only 21.1%. Of all the notifications for LNG and UPA, only 12.8% and 18.6% were
dispensed with an EC kit, respectively.
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Figure 2. (a) Quarterly cumulative incidence by type of geographical area; (b) annual cumulative incidence by type of
geographical area; (c) quarterly cumulative incidence in Catalonia. Significant differences: (a,b) * vs. urban area (p < 0.05);
(c) * p < 0.05.
3.2. User Profile
Of the medication, 80% was dispensed to women (753 cases) and 20% was collected
by men (188 cases). Almost all women (95.8%) stated that the medication was for their
own use; in the case of men, 92.5% said that they collected the medication for their partner
and 6.4% for a female fri d. The mean age of the women was 26.9 ± 7.8 years (median
of 26 years), whi e that of the men was 27.1 ± 9.0 years (median of 25 years), with no
significant differences observed.
In relation to the patients’ behavior, 55.8% of users said it was the first time that they
had taken t e edication (first-time user), while 44.2% stated t at they had taken it on
other occasions (repeat user). An increase was observed in the number of women who
requested the medication when they were repeat users compared to first-time users (85.8%
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vs. 75.4%, p < 0.001). The mean age of first-time and repeat users showed no significant
differences (26.7 ± 8.4 years and 27.2 ± 7.5 years, respectively, Table 1).
Table 1. Profile of users who used EC in Catalonia during the period 2018–2019.
Variables
Total (n = 941) Medication Collectedby Women (n = 753)
Medication Collected
by Men (n = 188)
n % n % n %
First-time user 525 55.8 396 75.4 129 24.6
Mean age (years) 26.7 ± 8.4 26.6 ± 8.2 27.2 ± 9.1
Condom used 338 64.4 241 60.9 97 75.2
Natural method used 129 24.6 104 26.3 25 19.4
Repeat user 416 44.2 357 85.8 59 14.2
Mean age 27.2 ± 7.5 27.3 ± 7.3 27.0 ± 8.8
Condom used 236 56.7 201 56.3 35 59.3
Natural method used 119 28.6 99 27.7 20 33.9
Almost one-quarter of repeat users (24.3%) confirmed that they used EC less than six
months previously, 23.1% used it more than six months but less than one year previously,
50.7% more than one year previously, and only 1.9% did not know this information.
Of the repeat users, 28.6% did not use any regular method of contraception compared
to 24.6% of first-time users, with no significant differences observed. However, the percent-
age of users who used condoms was lower in the repeat users compared with first-time
users (56.7% vs. 64.4%, p < 0.05, Table 1).
Notably, an analysis subgroup corresponded to 7.7% of cases in which the EC was
dispensed to minors. In this subgroup, the medication was collected by girls in 69.4%
of cases, significantly lower (p < 0.05) than the value for the group of repeat (85.8%) and
first-time users (75.4%); mean age was 16.1 ± 1.1 years (median age of 16.5 years). Of
the total number of cases, 26.4% of young people said they were repeat users; specifically,
42.1% said they had used the medication within the last six months. In general, in 31.6% of
cases, young people said they did not regularly use any method of contraception, while
68.4% used condoms.
3.3. Behavior of the Users
In 87.2% of cases, the users had collected the medication within 24 h of unprotected
sex; in 9.4%, in the following 25 to 48 h; and in 3.3%, after 48 h. In this regard, no statistically
significant differences were observed between first-time and repeat users.
With respect to users’ regular contraceptive method, the condom was the most widely
used method (60.1%). However, 25.7% of users stated that they did not use any barrier
contraceptive method.
Nevertheless, the joint analysis of the contraceptive methods used and risk behaviors
was particularly interesting. We observed that 41.7% of the subgroup of first-time users who
requested the medication between 25 and 48 h did not use any barrier method, increasing
to 50% in the subgroup of first-time users who requested the medication more than 48 h
after risky sexual intercourse. This was significantly higher than the proportion of first-time
users who obtained the medication within 24 h of unprotected sex and who used natural
methods (p < 0.01). Similarly, the use of natural methods in repeat users was 53.8% in the
subgroup who requested the medication after 48 h, significantly higher than in users who
obtained the medication within the first 24 h (p < 0.05) (Figure 3a).




Figure 3. Percentages of users according to the time of collection of the medication and their con-
traceptive behavior: first-time users and repeat users. Significant differences: * vs. < 24 h (p < 0.05). 
In the case of condoms, 50% and 38.9% of first-time users who collected the EC in the 
25–48 h interval and after 48 h, respectively, used this contraceptive method. These per-
centages are significantly lower than the percentage of women who obtained the medica-
tion within the first 24 h (Figure 3b). 
Likewise, when users were asked about their last menstrual period, 50% of first-time 
users and 30.8% of repeat users who took more than 48 h to seek EC did not remember 
the last time they had their period. Moreover, in 8.1% of cases, the women requested the 
EC more than 4 weeks after their last menstrual period. 
Eighty-two percent of users said that they had obtained the EC at the pharmacy in 
their neighborhood (Table 2). 
Table 2. Profile and behavior of users who used EC according to their area of residence. 
Variables 
Total Medication Collected by Women 
Medication Collected by 
Men 
n % n % n % 
Same area of 
residence 759 82.0 607 80.0 152 20.0 
Mean age 
(years) 
26.9 ± 8.0 27.0 ± 7.7 26.7 ± 8.9 
Repeat user 332 43.7 287 86.4 45 13.5 
Outside area of 
residence 167 18.0 135 80.8 32 19.2 
Mean age 
(years) 
26.9 ± 8.4 26.4 ± 8.1 29.1 ± 9.4 
Repeat user 77 46.1 65 84.4 12 15.6 
Only 18% of cases obtained the EC in areas outside their neighborhood. No age dif-
ferences were observed in the groups studied. When data from repeat users were ana-
lyzed, no differences were observed between users who obtained the medication outside 
their area of residence compared with the same area of residence (46.1% vs. 43.7%), while 
a higher percentage of women collected the medication compared to men, increasing from 
80% to 86.4% in the same area of residence and to 84.4% in outside areas (Table 2). 
  
Figure 3. (a,b) Percentages of users according to the ime of collecti n of the medication and their contra eptive behavior:
first-time users and repeat users. Significant differences: * vs. < 24 h (p < 0.05).
I the case of condoms, 50% and 38.9% of first-time us rs who collect d the EC in the
25–48 h interval and after 48 h re pectively, used this contraceptive method. These percent-
ages are significantly lower tha the percentage of w men who obtained the medication
within the first 24 h (Figure 3b).
Likewise, when users were asked about their last menstrual period, 50% of first-time
users and 30.8% of repeat users who took more than 48 h to seek EC did not remember the
last time they had their period. Moreover, in 8.1% of cases, the women requested the EC
more than 4 weeks after their last menstrual period.
Eighty-two percent of users said that they had obtained the EC at the pharmacy in
their neighborhood (Table 2).
Table 2. Profile and behavior of users who used EC according to their area of residence.
Variables
Total MedicationCollected by Women
Medication
Collected by Men
n % n % n %
Same area of residence 759 82.0 607 80.0 152 20.0
Mean age (years) 26.9 ± 8.0 27.0 ± 7.7 26.7 ± 8.9
Repeat user 332 43.7 287 86.4 45 13.5
Outside area of residence 167 18.0 135 80.8 32 19.2
Mean age (years) 26.9 ± 8.4 26.4 ± 8.1 29.1 ± 9.4
Repeat user 77 46.1 65 84.4 12 15.6
Only 18% of cases obtained the EC in areas outside their neighborhood. No age
differences were observed in the groups studied. When data from repeat users were
analyzed, no differences we observed between users who obt ine the medication
utside their ar a of residence compar d wi h the same area of esidence (46.1% vs. 43.7%),
whil a higher p c ntage of wom n collected the medication ompared to men, increasing
from 80% to 86.4% in t e same area of residence and to 84.4% in outside areas (Table 2).
3.4. Pharmacovigilance and Pharmaceutical Care
In relation to pharmacovigilance of the EC, 25 suspected adverse reactions were
detected (2.7%), the most common being menstrual delay, dizziness, and general malaise.
In approximately half of dispensations (53.9%), the community pharmacist performed
additional actions by providing the users with personalized information. The information
provided included dispensing pharmacotherapeutic advice and guidance on STDs, the
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rational use of the medication, possible interactions with other medications, the most
common side effects, problems related with the medication, and the use of alternative
contraceptive methods. Furthermore, in complex cases, the pharmacist referred the patient
to a gynecologist after providing advice on preventive measures and health education.
4. Discussion
Numerous studies have been conducted in recent years to determine the profile of
women seeking EC, factors associated with self-reported use, and sexual behavior of users.
The vast majority of these were performed using data obtained in primary care centers,
hospital or primary care emergency services, and family planning clinics. In contrast, little
data were obtained in community pharmacies through over-the-counter dispensing [11–13].
Contrasting the other studies, our study is one of the first carried out in the setting of a
community pharmacy. Given the proximity and importance of the pharmacist as a first-line
agent, we obtained a sufficiently representative sample that allowed us to characterize the
population that uses EC from the care dynamic, improving knowledge of the use of this
medication.
The results for the incidence of use of EC revealed that usage of this medication was
higher during holiday periods: it was highest in March 2019, which coincides with Easter
holidays, with an incidence of 244 per 100,000 women of reproductive age, and the summer
months of August and September 2018, with an incidence of 233 per 100,000 women
of reproductive age. Other national studies showed similar findings, reporting that the
months in which EC was most requested were August, September, and December during
the period from June 2002 to June 2004 [14].
Relevant incidence results were also obtained that show the behavioral pattern of
use of EC in Catalonia, a region of Spain situated in the south of Europe. Notably, the
incidence data per BHA obtained throughout the study year showed that the incidence of
the use of EC is greater in urban versus rural areas. This contrasts the results obtained in
a study conducted by the Catalan Ministry of Health during the period 2004 to 2007, in
which a comparative analysis was performed between two geographical areas, concluding
that, in the province of Lleida (rural area), the use of EC was higher than in the Barcelona
metropolitan area (urban area) [15].
The results reveal the repeated use of this contraceptive method, since in 44.2% of
cases users, said that it was not the first time they took this medication, which is consistent
with other national and international studies [14–16].
A systematic review of the profile of EC users based on a sample of 14 articles pub-
lished in Spain between 1999 and 2008 found that 9–60% of women used this medication
on more than one occasion [17]. Repeat use of this medication is linked to risky sexual
behavior among EC users [18,19]. In this study, the results show a higher percentage of
users who do not use any regular contraceptive method and the use of condoms is lower
with respect to users who take EC for the first time. Although previous studies sought to
demonstrate this, the findings are inconclusive.
With respect to the age profile of the users, although we did not detect age differ-
ences between first-time and repeat users in this study, a higher overall mean age was
observed in women who took EC (26.9 ± 7.8 years) in relation to data from most national
and international studies, where it was 20–24 years [11,14,20,21]. However, 7.7% of EC
dispensations were provided to minors, similar to that found in other studies [17]. These
latter data are accompanied by a high percentage of cases that did not use any regular
contraceptive method.
We observed that, in most cases, women used this medication within 24 h of having
unprotected sex (87.2%), which is comparable to that obtained in other studies [14,17]. We
also observed that repeat use of this medication was accompanied by more risky sexual
behavior in users who take EC more than 48 h after unprotected sex compared with those
who obtain it during the first few hours, including a lower percentage of users who use
condoms, and a higher percentage who use no contraceptive method.
J. Clin. Med. 2021, 10, 2793 9 of 11
With respect to the contraceptive methods used, all studies agree that the contra-
ceptive method most commonly used among EC users is the condom (60%), similar to
the percentage in this study [14,17,20,21]. However, the percentage of users who use no
contraceptive method in their sexual relationships (25.7%) is linked to a profile of users
who use EC repeatedly, together with a longer time between having unprotected sex and
seeking the medication, as described in other articles [14,22].
The results show a small but significant percentage of users to whom the EC was dis-
pensed more than 4 weeks after their LMP, an aspect that requires attention and corrective
measures since, according to product information sheets and therapeutic guidelines, its
use after the ovulation period is not effective [1–4].
We demonstrated that there is easy access to EC, as in most cases (according to Table 2),
users obtained the medication at the pharmacy in their area of residence. This also allows
us to assume that the users are non-judgmental and show greater confidence with regard to
healthcare professionals. Nevertheless, we found that in almost half of cases, the users who
collected the medication at pharmacies outside their neighborhood used this medication
repeatedly.
In addition, the Catalan sentinel pharmacy network enabled safety aspects in matters
of pharmacovigilance to be reinforced by identifying suspected drug-related adverse events
(DRAEs) for medicinal products marketed as EC. Fewer than 10% suspected DRAEs were
reported, which is consistent with previous studies within the national setting [14]. These
were mainly menstrual delay, dizziness, and general malaise, unlike other studies that
reported a higher number of cases related to nausea, vomiting, and headache, described in
other studies [7,8].
The demand for healthcare through low or very-low complexity processes remains
mainly with pharmacies, as they are the first level of care. Accordingly, the community
pharmacist has enormous potential, offering the possibility of monitoring the demand
for pharmaceutical indication related with the preclinical stages of pathological processes,
while having the responsibility of reporting the rational use of medicines and educating
the population to adopt safe sexual behavior. Contrary to expectation, the study findings
reveal low active participation of the pharmacist when dispensing the EC (53.9%), together
with little medication accompanied by an EC kit. For these reasons, and as pharmaceutical
care is essential for correct use of EC, more emphasis must be placed on the importance of
the community pharmacist and more proactive work must be encouraged.
The main limitation of the study is that not all users were receptive to providing
information at the time of dispensation of EC. However, since this occurrence was detected
in the pilot test, pharmacists were trained with specific training workshops in assertive
communication to address this issue [11].
Nevertheless, our study was able to show that the Catalan sentinel pharmacy network
serves as a robust system for epidemiological surveillance, thus enabling data to be obtained
on the profile and behavior of EC users in Catalonia. In this respect, a high percentage
of repeat users was detected, with risky sexual behaviors, suggesting that new measures
should be implemented to provide information on this method, together with educational
and preventive strategies. It also helped to define some of the real health indicators of the
general population.
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